Company intelligence / Profile preview

Valhalla Partners

Berwyn, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Valhalla Therapeutics is a privately-held biopharmaceutical company focused on developing novel small molecule therapies for metabolic and rare diseases. Based in Berwyn, Pennsylvania, the company leverages breakthrough research from Temple University to target pathways involved in insulin resistance and lysosomal storage disorders. Its lead program, VTX-31, is a designer small molecule intended to treat Type 2 Diabetes by inhibiting lipotoxicity induced by elevated fatty acid levels. Additionally, the company is advancing VTX-GD for neuronal Gaucher Disease and a RAGE inhibitor program for diabetic complications and chronic wound repair.

Therapeutic areas: EndocrinologyDermatologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Temple University

Beyond the preview

Go deeper on Valhalla Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Valhalla Partners.

Explore the full profile